IDEAYA Biosciences, Inc.

NasdaqGS:IDYA Stock Report

Market Cap: US$2.2b

IDEAYA Biosciences Future Growth

Future criteria checks 2/6

IDEAYA Biosciences is forecast to grow earnings and revenue by 8.6% and 68.7% per annum respectively. EPS is expected to grow by 9.9% per annum. Return on equity is forecast to be -29% in 3 years.

Key information

8.6%

Earnings growth rate

9.9%

EPS growth rate

Biotechs earnings growth27.5%
Revenue growth rate68.7%
Future return on equity-29.0%
Analyst coverage

Good

Last updated17 Dec 2024

Recent future growth updates

Recent updates

Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash

Dec 04

Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success

Sep 20

Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer?

Jul 08

Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'

Jun 18

Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?

Feb 22
Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?

Ideaya Biosciences: A Strong Bet In Targeted Oncology

Feb 16

Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week

Nov 09
Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

Oct 03
Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

IDEAYA Biosciences (NASDAQ:IDYA) Is In A Good Position To Deliver On Growth Plans

Jul 04
IDEAYA Biosciences (NASDAQ:IDYA) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate

Mar 10
We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

Nov 04
Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

Ideaya Biosciences: Prospects Rebound With Updated Uveal Melanoma Data

Oct 06

Ideaya Biosciences slides 8.5% aftermarket on $80M stock offering

Sep 14

Ideaya wins first milestone in GSK deal as cancer drug reaches clinical trials

Aug 29

Analysts Have Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Estimates By 6.2%

Aug 25
Analysts Have Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Estimates By 6.2%

IDEAYA Biosciences GAAP EPS of -$0.57 misses by $0.05, revenue of $11.34M beats by $4.75M

Aug 15

Earnings and Revenue Growth Forecasts

NasdaqGS:IDYA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202656-235-255-24513
12/31/202516-242-238-23514
12/31/20245-200-147-17513
9/30/20244-178-153-150N/A
6/30/202412-154-134-131N/A
3/31/202416-129-135-131N/A
12/31/202323-113-118-115N/A
9/30/202323-103-116-115N/A
6/30/202345-74-111-109N/A
3/31/202347-68-98-95N/A
12/31/202251-59-91-87N/A
9/30/202250-53-85-80N/A
6/30/202229-66-72-69N/A
3/31/202232-55-64-62N/A
12/31/202128-50-58-56N/A
9/30/202136-37-53-51N/A
6/30/202136-305052N/A
3/31/202127-315051N/A
12/31/202020-345555N/A
9/30/20209-405858N/A
6/30/2020N/A-46-43-42N/A
3/31/2020N/A-44-40-39N/A
12/31/2019N/A-42-41-39N/A
9/30/2019N/A-40-40-38N/A
6/30/2019N/A-42-39-36N/A
3/31/2019N/A-38-34-32N/A
12/31/2018N/A-34-29-28N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IDYA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IDYA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IDYA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IDYA's revenue (68.7% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: IDYA's revenue (68.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: IDYA is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 03:24
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

IDEAYA Biosciences, Inc. is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Zhiqiang ShuBerenberg
Justin ZelinBTIG